EyePoint Pharmaceuticals' lead product, EYP-1901, shows promising phase 2 results for wet AMD and DME. Read more about EYPT ...

Kodiak Sciences Inc. , today reported business highlights and financial results for the quarter ended September 30, 2024. "In the third quarter we hosted an Investor R&D Day in New York," said Victor ...

SOL-1 expected to be fully randomized by YE 2024 with topline data expected in Q4 2025 Active clinical trial sites now enrolling patients d ...

The FDA has approved Susvimo for the treatment of people with wet AMD who have previously responded to at least two anti-VEGF drugs such as Lucentis or Bayer and Regeneron's rival Eylea (aflibercept).

VEGF-directed drugs like Bayer and Regeneron’s Eylea (aflibercept) generate billions of dollars in sales every year from their use in AMD, DME, and other retinal disorders, and EyeBio reckons a ...

The table below is a review of notable updates that occurred in October 2024 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

Melting and boiling are changes of state.